THE OBLIQUE VIEW

## Decision by consensus: more political correctness or a genuine improvement in care?



#### Michael Norell

**Consultant Interventional** Cardiologist and PCI Programme Director, The Heart and Lung Centre, Wolverhampton, WV10 0QP

(m.norell@nhs.net)



We continue our series in which Consultant Interventionist Dr Michael Norell takes a sideways look at life in the cath lab...and beyond. In this column, he considers team working.

You will not need to be reminded that our summer months (such as they were) were witness to a wealth of sporting endeavours. In addition to the ubiquitous and oft-repeated terms like 'legacy', 'inspiration' and 'unbelievable', the word team also enjoyed a reasonable airing.

Extending the example of 'Team-GB', and employing a more cardiological perspective, I would submit the term 'Team *Heart*' for general consumption. Before readers assume that I am proposing a new Olympic competition in the form of the guickest call to balloon time, the largest number of new cardiac outpatients processed successfully in four hours, or the highest number of stents implanted during a 30-minute procedure, rest assured.

I am referring to the use of a multi-disciplinary team (MDT) approach in guiding the care of patients with heart disease. A recent national meeting in our own locality focused upon this topic, and I thought I would use this column to reflect some of the issues that were discussed.

#### How does it work and is it applied?

In the last year or two, international guidelines have advocated this approach supported more by a consensus of opinion than by any strong evidence base. There has been little provided in the way of examples or templates as to how such a collection of expertise is to be constructed, which cases are discussed and how a consensus is to be reached. How any recommendations are documented, whether they are executed or not and how reproducible the whole thing is, are further issues that most units could only dream of addressing - if indeed they were minded to in the first place.

A survey attempting to describe the national picture was reported and the results were certainly interesting. While many units have the semblance of an MDT process in place, the variation in frequency,

timing and attendance is marked, as are the type of cases discussed. Often the session allocated is not within 'office hours' and nor is it a recognised part of an agreed consultant job plan. Perhaps predictably, direct patient involvement in these meetings is exceedingly rare.

Our own unit has embraced this concept for some years and was able to shed some light onto the actual outcomes of MDT discussions. Increasingly often, further investigation with a pressure wire is advised in order to clarify the functional significance of angiographically questionable disease. This not only assists any proposed angioplasty (PCI) but also helps our surgical colleagues plan their own operative procedures.

As for how often the MDT result is actually carried out as recommended, the answer is most of the time. Sometimes, when offered, the patient will decline surgery (CABG) or more rarely - and less easy to understand - PCI, and occasionally targeted vessels are managed differently, both by the surgeon and by the interventional cardiologist. Rarely, new or unrecognised comorbidity will have emerged prior to any recommended procedure. making one or other approach less attractive.

I have always wondered just how reproducible the process is, and we have been able to examine this as well. I am pleased to say that when cases were re-presented to the MDT (in a blinded fashion) the same decisions were reached in the majority. Those cases in which either further investigation or an alternative revascularisation modality was advised were those in which either PCI or CABG would have been acceptable reflecting the genuine equipoise that exists with many of the cases that we treat.

In that event the patient's own preference becomes particularly important but how that involvement is stage-managed is another topic of debate. Their presence during the MDT discussion itself can be distressing or intimidating - for both parties - and if the consensus view is to be presented subsequently, perhaps in an outpatient clinic, then thought might be given as to who actually does this.





For the summary guidance and full technology appraisal guidance go to www.nice.org.uk/ta249 The only licensed oral anticoagulant to show superior efficacy to warfarin for both ischaemic and haemorrhagic stroke – Pradaxa® 150mg b.d.<sup>1-3</sup>

NICE now recommends Pradaxa® as an option for the prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation with one or more risk factors.4

**Pradaxa**® **150mg b.d.** Superior prevention of stroke and systemic embolism (p=0.0001) with similar rates of major bleeding vs warfarin<sup>1</sup>

**Pradaxa**® **110mg b.d.** Similar prevention of stroke and systemic embolism with significantly lower rates of major bleeding vs warfarin (p=0.003)<sup>5-7</sup>

Prescribing information can be found overleaf





Prescribing Information (SPAF — UK) PRADAXA\* (tabligation stool patients). Prescribing information indication: Prevention of stroke and rysteric ambients in adult patients with remarks with translation will color an early of the following in Seaters. Prevention state, and indication of the state of the following is Seaters. Prevention state, and indicates with remarks of the following is Seaters. Prevention state, and the state of the following is stated to a state of the following disbetor insidiars, commany where disease, an importance to extend with one of the following disbetor insidiars, commany where disease, an importance of the state and Administration of Plant in control or assessment of the state of t Prescribing Information (SPAF - UK) PRADAXA® (dabigatrum etexitate) Capsules containing 110 mg or 150 mg datogation etwilate jas mestate) Action: Overct thrombin invitator ladication: Prevention of attors and systemic emphasis in adult systems with named vice. Therefore one of Produce is not recommended in these patients. Contains Science Wellow (STTI) which is stated where in exactions. International Association and include aggregation agents. Story P-go inhibitors e.g. smicidizone, quintifies, weacomit, clarifferonypinco-special sections of the commended for conditional transition reduce Produce Desire and Contains and C Interval effect on the other of absorption of discipation. Fertility, pregnancy and factations, Aread programmy thoragy tearriest. Discovering in programmy universities Seally for essessary. Discounting create Aread programmy that is a proposal provider of the commonly recorded advance associations are beautiful proposal programmy to the proposal properties with standard therefore, posttomestical hardware properties and SEE. Common & PTOO, Interval programming properties and the properties of absorbing postportunity to 8,7100, and properties and interval programming the following programming of PTOO, Interval programming to 1500 mg. Prescriber should commit the formation of the following programming to 1500 mg. Prescriber should commit the formation of 150 mg. Prescriber should commit the formation of 150 mg. Prescriber should be programmed to 1500 mg. Prescriber should be prescribed to 15

Adverse events should be reported. Reporting forms and information can be found at <a href="https://www.mhra.goz.uk/yeidowcard">www.mhra.goz.uk/yeidowcard</a>, Adverse events should also be reported to Boehringer tigetheim Drug Salety en 0800 328 1827 (freephone).

References: 1. Boehringer togethern: Practical\* 150mg hard capturies Survivary of Product Oteracteristics 2. Pare NH. Materillers (Al.) et al. Product Survivary were sendern in normalistic small formation. N Eng. J. Met. 2011; 365:865-891; 3. Partie MN. Materillers (M. et al. Supplementary apprecias to Reversation versus surfaces in normalistic small fibrillation. N Eng. J. Med. 2011; 365:865-861. Available at http://www.men.org/authosport/10.1566/bcf.Materillogo/supplementary-parents-common colofosis, appendix pol Mccossed distriber 2012; 4. NCE fectioning Accessed Subsidiers 245; Dategorary electate for the presention of shakes and systemic entroders in small fibrillation. March 2012; Available at http://www.micr.org.udus219 [Accessed October 2012; 5. Boehreger Ingelters Pradate\* 110mg hard cognises Surmary of Product Chamilterists. Sciences (A.) Endered Vol. 2012; 5. Boehreger Ingelters Pradate\* 110mg hard cognises Surmary of Product Chamilterists. N Eng. J. Med. 2009; 361:1139-1151. 7, Connolly S. Espowett MC, et al. Newly identified events in the IR-C VI. Not. N Eng. J. Med. 2010; 361:1139-1151. 7, Connolly S. Espowett MC, et al. Newly identified events in the IR-C VI. Not. N. Eng. J. Med. 2010; 361:1139-1151. 7, Connolly S. Espowett MC, et al. Newly identified events in the IR-C VI. Not. N. Eng. J. Med. 2010; 361:1139-1151. 7, Connolly S. Espowett MC, et al. Newly identified events in the IR-C VI. N. N. Eng. J. Med. 2010; 361:1139-1151. 7, Connolly S. Espowett MC, et al. Newly identified events.

Date of preparation: Outploo 2012 Job code: UK/086-121610



For more information, including an educational pack, go to www.pradaxa.co.uk/SPAFeducationalpack or call the Pradaxa® information line on 0845 601 7880

### Cardiology) Limited Reproduction Prohibited

#### Is it valuable?

Most of the research around MDTs stems from cancer care where these are well established and found to be beneficial. Currently, evidence that they are of proven value in cardiology does not exist. However, as more cardiac units embrace the process there may well be an opportunity to look at and document outcomes before and after adopting this approach, and, thereby, build up an evidence base.

The psychology of team functioning is fascinating. There is always concern that the loudest voice or most senior figure will tend to influence the outcome. I can confirm that in our own experience, the latter is certainly not the case. Group dynamics will also come into play, with less confident individuals perhaps not feeling comfortable to express their views. Possibly, perverse decisions could result because smaller parties take refuge and confidence in the assumption that the larger group 'must surely know what it's doing'.

What – if any – are the medico legal implications of clinical management being derived by consensus? A common defence against alleged medical negligence is that a reasonable body of practitioners would have done the same thing - the application of the so-called Bolam test. A heart team might, therefore, be regarded as ideal in this regard in that it can effectively anticipate and supply the necessary rebuttal if called upon to do

But, supposing a practitioner acts in a different manner to that recommended by an MDT, what might then be the consequences? I suppose that as long as the reasoning is justified and documented then it must surely be up to the man - or woman - on the spot to make decisions about a procedure for which they are directly responsible.

#### **Expanding horizons**

We know that other areas of cardiology are embracing this process. Transcatheter aortic valve implantation (TAVI) is one example, given the complex nature of the cases discussed, as well as the technology and expense involved. The hospital and community management of heart failure is another topic that has come under this umbrella, guiding the use of cardiac resynchronisation therapy (CRT), as well as instigating end-of-life pathways for less fortunate patients.

Another important area is infective endocarditis (IE). This is a fruitful hunting ground for the litigious type and a common source of negligence claims in cardiology. It involves a long hospital admission with the potential of many complications, patient care often handed over from team to team, and - sadly - a mortality rate that has altered little over the last few decades. As a result, some units discuss its current cases of IE at their regular MDT meetings. This ensures that all parties are up to date with recent clinical developments or test results, and an opportunity is not missed to adjust treatment or consider surgical intervention.

#### Additional extras

A frequently forgotten spin off from the MDT is recruitment into research trials and registries. As the proportion of a unit's elective activity declines, identifying cases suitable for inclusion into studies, with sufficient time in which to assess and enrol them, becomes more difficult. Exposure to a departmental meeting in which any treatment plans can be discussed then allows the possibility that these cases might also contribute to the hospital's research programme.

Given the variety of MDT meetings about, it is likely that some form of harmonisation will be devised so that all units more or less do the same thing. Patients will need to be involved, but at a stage when we are confident that our processes are robust. Rather than proscriptive, we should view this as reassuring; the actual outcome that derives as a consensus from discussion is not as important as the transparency of decision making



## Learn and earn

Introducing our exciting new educational resource

Providing targeted CPD programmes for healthcare professionals

Written by leading clinicians to help you deliver best practice

Another resource brought to you by the UK's favourite cardiology journal

Sign up for our first programme

# Chronic stable angina

Available now free of charge at www.bjcardio.co.uk/learning

- Seven modules cover epidemiology and pathophysiology through to latest advances in diagnosis, treatment and prevention
- Endorsed by the British Junior Cardiologists'
  Association and HEART UK The Cholesterol
  Charity, our programme leads to 10 continuing
  professional development (CPD) credits
- ✓ Take single modules or the full programme with self-assessment sections for each module to complete at your own pace
- Your personal page records results and certificates can be printed for annual appraisal
- More programmes in development

"Very concise, practical module, with interesting data from other EU countries"
Epidemiology module user

"Good module discussing the pros and cons of the various drugs"
Secondary prevention and treatment module user

NOW LAUNCHED